Unattributed Code Systems

• http://example.com/codelists/CL_ntprobnp_unit
• http://example.org
• http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
• http://snomed.info/sct
• http://spor.ema.europa.eu/v1/example-reason
• http://unstats.un.org/unsd/methods/m49/m49.htm
• https://www.cas.org/support/documentation/chemical-substances
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
• https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
• https://www.nlm.nih.gov/mesh
• urn:ietf:bcp:47

Copyright Fragment

This fragment is available on index.html

Copyright and Registered Trademark Uses

• IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-10 Links: Table of Contents | QA Report | Version History | CC0 | Propose a change ( src )
• hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )
• 14.751 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - JSON Representation ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - TTL Representation ( src )
• : SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - XML Representation ( src )
• Artifact Author: Computable Publishing®: CTIS-to-FEvIR Converter: ( src )
• Artifact Author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: ( src )
• Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )
• Artifact Author: Computable Publishing®: [System]-to-FEvIR Converter: ( src )
• Change in Mean Diastolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367884. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367884. Computable resource at: https://fevir.net/resources/EvidenceVariable/367884#json. ( src )
• Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367943. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367943. Computable resource at: https://fevir.net/resources/Evidence/367943#json. ( src )
• Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367908. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367908. Computable resource at: https://fevir.net/resources/Evidence/367908#json. ( src )
• Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367907. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367907. Computable resource at: https://fevir.net/resources/Evidence/367907#json. ( src )
• Change in Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367882. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367882. Computable resource at: https://fevir.net/resources/EvidenceVariable/367882#json. ( src )
• Change in Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367891. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367891. Computable resource at: https://fevir.net/resources/EvidenceVariable/367891#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367941. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367941. Computable resource at: https://fevir.net/resources/Evidence/367941#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367904. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367904. Computable resource at: https://fevir.net/resources/Evidence/367904#json. ( src )
• Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367903. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367903. Computable resource at: https://fevir.net/resources/Evidence/367903#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367951. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367951. Computable resource at: https://fevir.net/resources/Evidence/367951#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367926. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367926. Computable resource at: https://fevir.net/resources/Evidence/367926#json. ( src )
• Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367925. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367925. Computable resource at: https://fevir.net/resources/Evidence/367925#json. ( src )
• Citation SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• Codes for use with the Classifier drop-down menu for FEvIR(R): Recommendation Justification Builder. ( src )
• Computable Publishing® augments digital publishing with machine-interpretable forms. Computable Publishing® offers publishers of any type (commercial, nonprofit, academic, government) the ability to extend their published works with computable (machine-interpretable) forms of expression, and users of any type support in using computable data to enhance, improve and achieve desired outcomes. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Executable app], version 4.9.1. Contributors: Computable Publishing LLC [Author]. In: Fast Evidence Interoperability Resources (FEvIR) Platform. Published June 04, 2021. Revised October 09, 2023. Accessed November 25, 2023. Available at: https://fevir.net/ctgovconvert. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter converts ClinicalTrials.gov JSON to FEvIR Resources in FHIR® JSON. • Enter an NCT Identifier (NCTID) and click Submit. • FHIR Resources will be created for all Protocol and Results Section Data in the ClinicalTrials.gov record. • For related articles listed in MEDLINE, the Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter automates use of the Computable Publishing®: MEDLINE-to-FEvIR Converter. ( src )
• Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter is one of the many Converter tools on the FEvIR Platform. • Converter Tools transform data between known structured forms and the FHIR standard form. • The FEvIR Platform provides access to an array of tools which enable creating and viewing scientific knowledge in standard-based, machine-interpretable units called Resources. ( src )
• Copyright © 2011 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved. ( src )
• Copyright © 2013 Elsevier Inc. All rights reserved. ( src )
• Copyright © 2013 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved. ( src )
• Copyright © 2015 Elsevier Inc. All rights reserved. ( src )
• Copyright © 2015 Elsevier Ltd. All rights reserved. ( src )
• Copyright © 2021 Massachusetts Medical Society. All rights reserved. ( src )
• Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ( src )
• Defines the content expected to be rendered in all representations of the artifact. The (c) symbol should NOT be included in this string. It is expected to be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )
• Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: CTIS-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 346485. Revised 2025-07-17. Available at: https://fevir.net/resources/ResearchStudy/346485. Computable resource at: https://fevir.net/resources/ResearchStudy/346485#json. ( src )
• Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367879. Revised 2025-08-18. Available at: https://fevir.net/resources/ResearchStudy/367879. Computable resource at: https://fevir.net/resources/ResearchStudy/367879#json. ( src )
• Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions ( src )
• Example Citation: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• GLUCAGEN® and GLUCAGEN® Hypokit 1 mg (glucagon) Product Monograph. Mississauga, Ontario: Novo Nordisk Canada Inc.; 2014. http://www.paladin-labs.com/our_products/PM_GlucaGen_EN.pdf. Accessed 26 September 2015. ( src )
• Health-related Quality of Life (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367890. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367890. Computable resource at: https://fevir.net/resources/EvidenceVariable/367890#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370509. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370509. Computable resource at: https://fevir.net/resources/EvidenceVariable/370509#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367924. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367924. Computable resource at: https://fevir.net/resources/Evidence/367924#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367923. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367923. Computable resource at: https://fevir.net/resources/Evidence/367923#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370508. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370508. Computable resource at: https://fevir.net/resources/EvidenceVariable/370508#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367922. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367922. Computable resource at: https://fevir.net/resources/Evidence/367922#json. ( src )
• Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367921. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367921. Computable resource at: https://fevir.net/resources/Evidence/367921#json. ( src )
• Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367949. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367949. Computable resource at: https://fevir.net/resources/Evidence/367949#json. ( src )
• Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367950. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367950. Computable resource at: https://fevir.net/resources/Evidence/367950#json. ( src )
• Mean Change in Blood Urea Nitrogen (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367901. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367901. Computable resource at: https://fevir.net/resources/EvidenceVariable/367901#json. ( src )
• Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367957. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367957. Computable resource at: https://fevir.net/resources/Evidence/367957#json. ( src )
• Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367938. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367938. Computable resource at: https://fevir.net/resources/Evidence/367938#json. ( src )
• Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367937. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367937. Computable resource at: https://fevir.net/resources/Evidence/367937#json. ( src )
• Mean Change in Serum Creatinine (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367902. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367902. Computable resource at: https://fevir.net/resources/EvidenceVariable/367902#json. ( src )
• Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367958. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367958. Computable resource at: https://fevir.net/resources/Evidence/367958#json. ( src )
• Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367940. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367940. Computable resource at: https://fevir.net/resources/Evidence/367940#json. ( src )
• Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367939. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367939. Computable resource at: https://fevir.net/resources/Evidence/367939#json. ( src )
• Mean Change in Serum Potassium (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367899. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367899. Computable resource at: https://fevir.net/resources/EvidenceVariable/367899#json. ( src )
• Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367955. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367955. Computable resource at: https://fevir.net/resources/Evidence/367955#json. ( src )
• Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367934. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367934. Computable resource at: https://fevir.net/resources/Evidence/367934#json. ( src )
• Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367933. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367933. Computable resource at: https://fevir.net/resources/Evidence/367933#json. ( src )
• Mean Change in Serum Sodium (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367900. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367900. Computable resource at: https://fevir.net/resources/EvidenceVariable/367900#json. ( src )
• Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367956. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367956. Computable resource at: https://fevir.net/resources/Evidence/367956#json. ( src )
• Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367936. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367936. Computable resource at: https://fevir.net/resources/Evidence/367936#json. ( src )
• Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367935. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367935. Computable resource at: https://fevir.net/resources/Evidence/367935#json. ( src )
• Mean Diastolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367885. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367885. Computable resource at: https://fevir.net/resources/EvidenceVariable/367885#json. ( src )
• Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367944. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367944. Computable resource at: https://fevir.net/resources/Evidence/367944#json. ( src )
• Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367910. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367910. Computable resource at: https://fevir.net/resources/Evidence/367910#json. ( src )
• Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367909. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367909. Computable resource at: https://fevir.net/resources/Evidence/367909#json. ( src )
• Mean Systolic Blood Pressure (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367883. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367883. Computable resource at: https://fevir.net/resources/EvidenceVariable/367883#json. ( src )
• Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367942. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367942. Computable resource at: https://fevir.net/resources/Evidence/367942#json. ( src )
• Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367906. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367906. Computable resource at: https://fevir.net/resources/Evidence/367906#json. ( src )
• Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367905. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367905. Computable resource at: https://fevir.net/resources/Evidence/367905#json. ( src )
• Medication Adherence (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367889. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367889. Computable resource at: https://fevir.net/resources/EvidenceVariable/367889#json. ( src )
• Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367948. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367948. Computable resource at: https://fevir.net/resources/Evidence/367948#json. ( src )
• Medication Adherence at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367920. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367920. Computable resource at: https://fevir.net/resources/Evidence/367920#json. ( src )
• Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367919. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367919. Computable resource at: https://fevir.net/resources/Evidence/367919#json. ( src )
• Methods Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. They were randomly assigned to receive supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care or standard of care medications alone. The primary endpoint was the proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization. This trial was registered with clinicaltrials.gov, NCT04401202. ( src )
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. ( src )
• NCT03640312 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367881. Revised 2025-08-18. Available at: https://fevir.net/resources/Group/367881. Computable resource at: https://fevir.net/resources/Group/367881#json. ( src )
• Number of Patients Requiring Step up Treatment (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367887. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367887. Computable resource at: https://fevir.net/resources/EvidenceVariable/367887#json. ( src )
• Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367946. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367946. Computable resource at: https://fevir.net/resources/Evidence/367946#json. ( src )
• Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367916. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367916. Computable resource at: https://fevir.net/resources/Evidence/367916#json. ( src )
• Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367915. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367915. Computable resource at: https://fevir.net/resources/Evidence/367915#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367897. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367897. Computable resource at: https://fevir.net/resources/EvidenceVariable/367897#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367953. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367953. Computable resource at: https://fevir.net/resources/Evidence/367953#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367930. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367930. Computable resource at: https://fevir.net/resources/Evidence/367930#json. ( src )
• Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367929. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367929. Computable resource at: https://fevir.net/resources/Evidence/367929#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367896. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367896. Computable resource at: https://fevir.net/resources/EvidenceVariable/367896#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367952. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367952. Computable resource at: https://fevir.net/resources/Evidence/367952#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367928. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367928. Computable resource at: https://fevir.net/resources/Evidence/367928#json. ( src )
• Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367927. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367927. Computable resource at: https://fevir.net/resources/Evidence/367927#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367888. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367888. Computable resource at: https://fevir.net/resources/EvidenceVariable/367888#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367947. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367947. Computable resource at: https://fevir.net/resources/Evidence/367947#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367918. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367918. Computable resource at: https://fevir.net/resources/Evidence/367918#json. ( src )
• Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367917. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367917. Computable resource at: https://fevir.net/resources/Evidence/367917#json. ( src )
• Proportion of Patients With Hypertension Control (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367886. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367886. Computable resource at: https://fevir.net/resources/EvidenceVariable/367886#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370507. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370507. Computable resource at: https://fevir.net/resources/EvidenceVariable/370507#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367914. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367914. Computable resource at: https://fevir.net/resources/Evidence/367914#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367913. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367913. Computable resource at: https://fevir.net/resources/Evidence/367913#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370506. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/370506. Computable resource at: https://fevir.net/resources/EvidenceVariable/370506#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367912. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367912. Computable resource at: https://fevir.net/resources/Evidence/367912#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367911. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367911. Computable resource at: https://fevir.net/resources/Evidence/367911#json. ( src )
• Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367945. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367945. Computable resource at: https://fevir.net/resources/Evidence/367945#json. ( src )
• Rate of Adverse Events of Special Interest (NCT03640312) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367898. Revised 2025-08-18. Available at: https://fevir.net/resources/EvidenceVariable/367898. Computable resource at: https://fevir.net/resources/EvidenceVariable/367898#json. ( src )
• Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367954. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367954. Computable resource at: https://fevir.net/resources/Evidence/367954#json. ( src )
• Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367932. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367932. Computable resource at: https://fevir.net/resources/Evidence/367932#json. ( src )
• Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367931. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367931. Computable resource at: https://fevir.net/resources/Evidence/367931#json. ( src )
• Results Section for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367880. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/367880. Computable resource at: https://fevir.net/resources/Composition/367880. ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - JSON Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - TTL Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2 ( src )
• The (c) symbol should NOT be included in this string. It will be added by software when rendering the notation. Full details about licensing, restrictions, warrantees, etc. goes in the more general 'copyright' element. ( src )
• The purpose of this research was to describe and interpret the positive body image experiences of women actively engaged in pole fitness. A total of seven women between the ages of 20 and 36 years participated in semistructured one-on-one interviews and follow-up interviews. Participant observation was also used to generate data. Data were analyzed using an interpretative phenomenological analysis approach, and the positive body image experiences of women are represented by five themes: (a) observation and exposure fostering body acceptance, (b) performance promoting self-confidence, (c) personal growth and sexual expression, (d) unconditional community support creates comfort, and (e) body appreciation through physical skill development. Findings suggest that women engaging in pole fitness may experience positive body image, and the words of participants provide insight into the components of pole fitness that may foster positive body image. Pole fitness may provide a unique exercise context whereby women can develop and maintain positive body image. ( src )
• The short copyright declaration (e.g. (c) '2015+ xyz organization' should be sent in the copyrightLabel element. ( src )
• This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: Composition/256358, Composition/343018... Show 32 more , ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, EGFR_45_59, Ethnic_Group, Group/267506, Group/279346, Group/279347, Group/282882, Group/297750, Hypertension_Control_at_12_weeks, M11Report, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, QUARTET_Eligibility_Criteria, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old and Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis ( src )
• This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * StatisticAttribute Estimate Type: AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis... Show 42 more , ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, MeanDiffA1c2016metaAnalysis, NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_2_OutcomeAnalysis_13_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_3_OutcomeAnalysis_14_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_5_OutcomeAnalysis_16_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_6_OutcomeAnalysis_17_BetweenGroupAnalysis_OG000_OG001, NCT03640312_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_0_OutcomeAnalysis_1_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_1_OutcomeAnalysis_2_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_2_OutcomeAnalysis_3_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_3_OutcomeAnalysis_4_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_4_OutcomeAnalysis_5_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_5_OutcomeAnalysis_6_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_6_OutcomeAnalysis_7_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001 and NCT03640312_secondaryOutcomeMeasure_8_OutcomeAnalysis_10_BetweenGroupAnalysis_OG000_OG001 * StatisticCertaintyRating: ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study and ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study * EvidenceDirectness: Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19 and Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY * LibraryType: Library/179606, Library/179618... Show 4 more , Library/179632, SearchResults, SystematicReviewExcludedStudies and SystematicReviewIncludedStudies * List Empty Reasons: Composition/178426, Composition/179465... Show 7 more , Composition/179466, Composition/179467, Composition/179699, Composition/236538, Composition/256358, Composition/292951 and Composition/372776 * Organization type: Computable_Publishing_LLC * PlanDefinitionType: PlanDefinition/179468, PlanDefinition/179554 and RecommendationPlan * ResearchStudyObjectiveType: NCT03640312_FHIR_Transform * ResearchStudyPhase: NCT03421379_FHIR_Transform_M11_IGBJ and NCT03640312_FHIR_Transform * ResearchStudyPrimaryPurposeType: NCT03421379_FHIR_Transform_M11_IGBJ and NCT03640312_FHIR_Transform * StatisticStatisticType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, AllCauseMortality2022metaAnalysis... Show 92 more , AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, MeanDiffA1c2016metaAnalysis, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883 and Severe_gastrointestinal_events_from_MAGICapp_313965 * StatisticSynthesisType: AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis... Show 35 more , ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, MeanDiffA1c2016metaAnalysis, NMA_Diabetes and SingleStudyEvidence * UsageContextType: Citation/5296, Citation/7636, Citation/7638, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19 and NCT03640312_Results * identifierType: ADAS_Cog11_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, ActivityDefinition/375159... Show 658 more , ActivityDefinition/375181, Add_on_Amlodipine_at_6_weeks, Adults_with_type_2_diabetes, Adults_with_type_2_diabetes_with_moderate_CV_risk, Adverse_event_free_and_hypertension_control_at_12_weeks, Age, Age_with_comparator, Age_with_intervention, Aircraft_Type_with_comparator, Aircraft_Type_with_intervention, AllCauseMortality2022metaAnalysis, AllCauseMortalityControlGroup2022metaAnalysis, All_cause_mortality313876, All_cause_mortality313956, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313876, All_cause_mortality_Comparator_Evidence_from_MAGICapp_313956, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313876, All_cause_mortality_Intervention_Evidence_from_MAGICapp_313956, All_cause_mortality_from_MAGICapp_313876, All_cause_mortality_from_MAGICapp_313956, Altitude, Altitude_comparing_intervention_vs_comparator, Altitude_for_enrolled_group, Altitude_for_screened_group, Altitude_with_comparator, Altitude_with_intervention, An_example_of_OutcomeDefinition_Profile_which_is_a_conceptual_group_used_to_provided_a_definition_for_an_EvidenceVariable, Analyte_type_of_the_sample, ArtifactAssessment/104064, ArtifactAssessment/104192, ArtifactAssessment/104193, ArtifactAssessment/104194, ArtifactAssessment/104195, ArtifactAssessment/104196, ArtifactAssessment/171898, ArtifactAssessment/179448, ArtifactAssessment/179469, ArtifactAssessment/179515, ArtifactAssessment/179692, ArtifactAssessment/179693, ArtifactAssessment/179694, ArtifactAssessment/179698, ArtifactAssessment/179700, ArtifactAssessment/181452, ArtifactAssessment/307449, ArtifactAssessment/385882, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17, Bariatric_Surgery_RYGB_VSG_LAGB_BPD, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Medical_Group, BaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group, Birthdate, Body_site_where_sample_was_collected, Body_weight109570, Body_weight109588, Body_weight_Comparator_Evidence_from_MAGICapp_109570, Body_weight_Comparator_Evidence_from_MAGICapp_109588, Body_weight_Intervention_Evidence_from_MAGICapp_109570, Body_weight_Intervention_Evidence_from_MAGICapp_109588, Body_weight_from_MAGICapp_109570, Body_weight_from_MAGICapp_109588, CIBIC_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, COVID_19PneumoniaHospitalizedAdult, CTIS2024_516402_32_00_Eligibility_Criteria, CTIS2024_516402_32_00_Primary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_1, CTIS2024_516402_32_00_Secondary_Outcome_2, CTIS2024_516402_32_00_Secondary_Outcome_3, CTIS2024_516402_32_00_Secondary_Outcome_4, CTIS2024_516402_32_00_Secondary_Outcome_5, CTIS2024_516402_32_00_Secondary_Outcome_6, CTIS2024_516402_32_00_Secondary_Outcome_7, CTIS2024_516402_32_00_Secondary_Outcome_8, CTIS_2024_516402_32_00_FHIR_Transform, Cardiovascular_mortality313877, Cardiovascular_mortality313957, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Comparator_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313877, Cardiovascular_mortality_Intervention_Evidence_from_MAGICapp_313957, Cardiovascular_mortality_from_MAGICapp_313877, Cardiovascular_mortality_from_MAGICapp_313957, Case_id, Change_in_Mean_Diastolic_Blood_Pressure_NCT03640312, Change_in_Mean_Systolic_Blood_Pressure_NCT03640312, Citation/104116, Citation/121719, Citation/139859, Citation/139860, Citation/153881, Citation/179558, Citation/179559, Citation/179560, Citation/179561, Citation/179594, Citation/179595, Citation/179596, Citation/179597, Citation/179598, Citation/179599, Citation/179600, Citation/179601, Citation/179602, Citation/179603, Citation/179604, Citation/179605, Citation/179613, Citation/179615, Citation/179616, Citation/179617, Citation/179621, Citation/179622, Citation/179623, Citation/179624, Citation/179625, Citation/179626, Citation/179627, Citation/179628, Citation/179629, Citation/179630, Citation/179631, Citation/179637, Citation/247416, Citation/264329, Citation/267246, Citation/267247, Citation/267496, Citation/267497, Citation/267498, Citation/267499, Citation/267500, Citation/267501, Citation/29812, Citation/306957, Citation/32137, Citation/33089, Citation/33399, Citation/33400, Citation/367878, Citation/385938, Citation/5296, Citation/58, Citation/7636, Citation/7638, CodeSystemRecommendationJustification, ComparativeBaselineMeasureEvidence_Age_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeBaselineMeasureEvidence_BMI_in_2018_Norwegian_Cohort_Surgical_Group_vs_Medical_Group, ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort, ComparativeEvidence_Bariatric_Surgery_effect_for_ADA_triple_outcome_at_5_years_Diabetes_Surgery_Study, ComparativeEvidence_Bypass_surgery_effects_on_Additional_GI_surgical_procedure_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Myocardial_infarction_or_stroke_in_Swedish_Obese_Subjects_SOS_study, ComparativeEvidence_Bypass_surgery_effects_on_New_onset_depression_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Remission_of_diabetes_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Bypass_surgery_effects_on_Treatment_with_opioids_in_JAMA_2018_Norwegian_cohort_study, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Courcoulas_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Cummings_2016, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ding_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Dixon_2008, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Halperin_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Ikramuddin_2015, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Liang_2013, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2012_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Mingrone_2015_DIBASY_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Parikh_2014, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2012_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Schauer_2014_STAMPEDE_trial, ComparativeEvidence_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_in_Wentworth_2014, ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial, ComparatorDefinition_Obese_patients_18_years_old_without_bariatric_surgery, ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, ComparatorOnlyEvidence_Additional_GI_surgical_procedure_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Myocardial_infarction_or_stroke_without_bariatric_surgery_Control_Group_in_Swedish_Obese_Subjects_SOS_study, ComparatorOnlyEvidence_New_onset_depression_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Remission_of_diabetes_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, ComparatorOnlyEvidence_Treatment_with_opioids_without_bariatric_surgery_Control_Group_in_JAMA_2018_Norwegian_cohort_study, Composition/104215, Composition/104383, Composition/178426, Composition/179465, Composition/179466, Composition/179467, Composition/179699, Composition/236537, Composition/236538, Composition/236951, Composition/256358, Composition/292951, Composition/307245, Composition/307248, Composition/312172, Composition/312203, Composition/318262, Composition/342828, Composition/343007, Composition/343018, Composition/370502, Composition/370503, Composition/370504, Composition/370505, Composition/370512, Composition/372776, Composition/375280, Computable_Publishing_LLC, ConceptualCohortDefinition_At_least_2_risk_factors_for_stroke, ConceptualCohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, ConceptualCohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, ConceptualCohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, ConceptualCohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years, ConceptualCohortDefinition_Cardiovascular_event, ConceptualCohortDefinition_Heart_failure_based_on_Phenotypes, ConceptualCohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration, ConceptualCohortDefinition_Nonfatal_myocardial_infarction, ConceptualCohortDefinition_Nonfatal_stroke, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter, ConceptualCohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, ConceptualCohortDefinition_Proxy_criteria_for_surgical_candidates, ConceptualCohortDefinition_Severe_obesity, ConceptualComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, ConceptualComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis, ConceptualExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin, Condition_code, Critically_appraised_summary_of_primary_outcome_of_multi_platform_RCT_of_anticoagulation_for_non_critically_ill_patients_with_COVID_19, Cs_ebm_ig, Death_or_Major_Traumatic_Injury_30_days_after_Impact_comparing_intervention_vs_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_comparator, Death_or_Major_Traumatic_Injury_30_days_after_Impact_with_intervention, Death_or_Major_Traumatic_Injury_on_Impact_comparing_intervention_vs_comparator, Declined_randomization_in_PARACHUTE_Study, Deemed_unsuitable_by_investigator_in_PARACHUTE_Trial, DeviceDefinition/179899, Diabetic_ketoacidosis313962, Diabetic_ketoacidosis_Comparator_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962, Diabetic_ketoacidosis_from_MAGICapp_313962, Diastolic_blood_pressure_at_12_weeks, DichotomousIntendedOutcome_Death_or_Major_Traumatic_Injury_within_30_days, DocumentReference/367832, DocumentReference/367833, EGFR_45_59, End_stage_kidney_disease313880, End_stage_kidney_disease313960, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880, End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960, End_stage_kidney_disease_from_MAGICapp_313880, End_stage_kidney_disease_from_MAGICapp_313960, Ethnic_Group, Ethnic_Group_with_comparator, Ethnic_Group_with_intervention, EvidenceReportSectionCode_Value_Set, EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery, EvidenceVariableHandlingExtensionValueSet, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Add_on_Amlodipine_at_6_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Diastolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Hypertension_Control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Medication_Adherence_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Control_Group, Evidence_for_Results_for_Systolic_blood_pressure_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group, Example_EndpointAnalysisPlan_from_PHUSE_Lilly_Redacted_Protocol_EBMonFHIR_IG_Version, Example_Variable_Definition_for_EBMonFHIR_IG, Example_variable_definition_for_the_EBMonFHIR_IG, Excluded_from_PARACHUTE_Study, ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort, ExposureVariable_Age_as_continuous_variable, ExposureVariable_Body_Mass_Index_as_continuous_variable, Family_History_of_Parachute_Use, Family_History_of_Parachute_Use_with_comparator, Family_History_of_Parachute_Use_with_intervention, Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY, Frequent_Flier, Frequent_Flier_with_comparator, Frequent_Flier_with_intervention, GLU_J, Gender, Genital_infection313964, Genital_infection_Comparator_Evidence_from_MAGICapp_313964, Genital_infection_Intervention_Evidence_from_MAGICapp_313964, Genital_infection_from_MAGICapp_313964, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85390_I_85789, Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798, Group/236534, Group/236535, Group/236948, Group/236949, Group/264323, Group/264328, Group/265092, Group/265093, Group/267506, Group/270503, Group/279340, Group/279346, Group/279347, Group/282882, Group/282891, Group/282899, Group/292955, Group/297486, Group/297487, Group/297488, Group/297489, Group/297750, Group/306655, Group/306657, Group/306658, Group/306659, Group/306660, Group/307440, Group/33395, Group/370701, Group/370702, Group/372797, Group/375175, Group/375182, Group/375279, GroupAssignment_Bariatric_Surgery_vs_no_bariatric_surgery, GroupAssignment_ExposureDefinition_Bariatric_Surgery_RYGB_VSG_LAGB_BPD_vs_ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, GroupAssignment_ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort_vs_ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, GroupAssignment_GLP_1_RA_vs_Standard_care, GroupAssignment_Jumping_from_aircraft_with_parachute_vs_Jumping_from_aircraft_with_empty_backpack, GroupAssignment_Non_Participants_vs_Enrolled_Participants, GroupAssignment_Quadpill_vs_Candesartan, GroupAssignment_Roux_en_Y_gastric_bypass_or_Biliopancreatic_Diversion_vs_medical_treatment, GroupAssignment_Roux_en_Y_gastric_bypass_surgery_vs_Lifestyle_intensive_medical_management_intervention_alone, GroupAssignment_Roux_en_Y_gastric_bypass_vs_medical_treatment, GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA, GroupAssignment_high_dose_xanomeline_vs_low_dose_xanomeline_vs_placebo, Health_Survey_Score_Mental_Health_Subscore, Health_Survey_Score_Mental_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Mental_Health_Subscore_with_comparator, Health_Survey_Score_Mental_Health_Subscore_with_intervention, Health_Survey_Score_Physical_Health_Subscore, Health_Survey_Score_Physical_Health_Subscore_comparing_intervention_vs_comparator, Health_Survey_Score_Physical_Health_Subscore_with_comparator, Health_Survey_Score_Physical_Health_Subscore_with_intervention, Health_Survey_Score_Total, Health_Survey_Score_Total_comparing_intervention_vs_comparator, Health_Survey_Score_Total_with_comparator, Health_Survey_Score_Total_with_intervention, Health_related_Quality_of_Life_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Mental_Health_T_score_PROMIS_at_NCT03640312, Health_related_Quality_of_Life_at_12_weeks_Change_in_Physical_Health_T_score_PROMIS_at_NCT03640312, Health_related_quality_of_life109569, Health_related_quality_of_life109587, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Comparator_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109569, Health_related_quality_of_life_Intervention_Evidence_from_MAGICapp_109587, Health_related_quality_of_life_from_MAGICapp_109569, Health_related_quality_of_life_from_MAGICapp_109587, Heart_failure313881, Heart_failure313961, Heart_failure_Comparator_Evidence_from_MAGICapp_313881, Heart_failure_Comparator_Evidence_from_MAGICapp_313961, Heart_failure_Intervention_Evidence_from_MAGICapp_313881, Heart_failure_Intervention_Evidence_from_MAGICapp_313961, Heart_failure_from_MAGICapp_313881, Heart_failure_from_MAGICapp_313961, Height_with_comparator, Height_with_intervention, High_Blood_Pressure_Medication_Value_Set, History_of_Acrophobia, History_of_Acrophobia_with_comparator, History_of_Acrophobia_with_intervention, History_of_Broken_Bones, History_of_Broken_Bones_with_comparator, History_of_Broken_Bones_with_intervention, History_of_Parachute_Use, History_of_Parachute_Use_with_comparator, History_of_Parachute_Use_with_intervention, Hypertension_Control_at_12_weeks, ICD10GM_Terminale_Codes, IV_remdesivir_200_mg_then_100_mg_day_for_9_days, Injury_Severity_Score_30_days_after_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_30_days_after_Impact_with_comparator, Injury_Severity_Score_30_days_after_Impact_with_intervention, Injury_Severity_Score_on_Impact_comparing_intervention_vs_comparator, Injury_Severity_Score_on_Impact_with_comparator, Injury_Severity_Score_on_Impact_with_intervention, International_vs_Domestic_Flight, International_vs_Domestic_Flight_with_comparator, International_vs_Domestic_Flight_with_intervention, InterventionOnlyEvidence_Additional_GI_surgical_procedure_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_New_onset_depression_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Remission_of_diabetes_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, InterventionOnlyEvidence_Treatment_with_opioids_with_bariatric_surgery_Intervention_Group_in_JAMA_2018_Norwegian_cohort_study, Investigator, Investigator_by_treatment_interaction_for_ADAS_Cog11_ANCOVA, LBDGLUSI, LBXGLU, Library/179606, Library/179618, Library/179632, List/179470, List/179579, List/179585, List/179800, List/307202, List/307246, List/307247, List/312201, List/312205, List/375184, MeanDiffA1c2016metaAnalysis, Mean_Change_in_Blood_Urea_Nitrogen_NCT03640312, Mean_Change_in_Serum_Creatinine_NCT03640312, Mean_Change_in_Serum_Potassium_NCT03640312, Mean_Change_in_Serum_Sodium_NCT03640312, Mean_Diastolic_Blood_Pressure_NCT03640312, Mean_Systolic_Blood_Pressure_NCT03640312, Median_Age_SD, Medication_Adherence_NCT03640312, Medication_Adherence_at_12_weeks, MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs, Mortality14Day, NCT03421379_FHIR_Transform_M11_IGBJ, NCT03640312_Eligibility_Criteria, NCT03640312_FHIR_Transform, NCT03640312_Results, NCT03640312_otherOutcomeMeasure_0_OG000, NCT03640312_otherOutcomeMeasure_0_OG001, NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_1_OG000, NCT03640312_otherOutcomeMeasure_1_OG001, NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_2_OG000, NCT03640312_otherOutcomeMeasure_2_OG001, NCT03640312_otherOutcomeMeasure_2_OutcomeAnalysis_13_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_3_OG000, NCT03640312_otherOutcomeMeasure_3_OG001, NCT03640312_otherOutcomeMeasure_3_OutcomeAnalysis_14_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_4_OG000, NCT03640312_otherOutcomeMeasure_4_OG001, NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_5_OG000, NCT03640312_otherOutcomeMeasure_5_OG001, NCT03640312_otherOutcomeMeasure_5_OutcomeAnalysis_16_BetweenGroupAnalysis_OG000_OG001, NCT03640312_otherOutcomeMeasure_6_OG000, NCT03640312_otherOutcomeMeasure_6_OG001, NCT03640312_otherOutcomeMeasure_6_OutcomeAnalysis_17_BetweenGroupAnalysis_OG000_OG001, NCT03640312_primaryOutcomeMeasure_0_OG000, NCT03640312_primaryOutcomeMeasure_0_OG001, NCT03640312_primaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_0_OG000, NCT03640312_secondaryOutcomeMeasure_0_OG001, NCT03640312_secondaryOutcomeMeasure_0_OutcomeAnalysis_1_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_1_OG000, NCT03640312_secondaryOutcomeMeasure_1_OG001, NCT03640312_secondaryOutcomeMeasure_1_OutcomeAnalysis_2_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_2_OG000, NCT03640312_secondaryOutcomeMeasure_2_OG001, NCT03640312_secondaryOutcomeMeasure_2_OutcomeAnalysis_3_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG000, NCT03640312_secondaryOutcomeMeasure_3_12_weeks_OG001, NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG000, NCT03640312_secondaryOutcomeMeasure_3_6_weeks_OG001, NCT03640312_secondaryOutcomeMeasure_3_OutcomeAnalysis_4_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_4_OG000, NCT03640312_secondaryOutcomeMeasure_4_OG001, NCT03640312_secondaryOutcomeMeasure_4_OutcomeAnalysis_5_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_5_OG000, NCT03640312_secondaryOutcomeMeasure_5_OG001, NCT03640312_secondaryOutcomeMeasure_5_OutcomeAnalysis_6_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_6_OG000, NCT03640312_secondaryOutcomeMeasure_6_OG001, NCT03640312_secondaryOutcomeMeasure_6_OutcomeAnalysis_7_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Mental_Health_T_score_OPEN_PROMIS_CLOSE_OG000, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Mental_Health_T_score_OPEN_PROMIS_CLOSE_OG001, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG000, NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_8_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001, NCT03640312_secondaryOutcomeMeasure_8_OG000, NCT03640312_secondaryOutcomeMeasure_8_OG001, NCT03640312_secondaryOutcomeMeasure_8_OutcomeAnalysis_10_BetweenGroupAnalysis_OG000_OG001, NMA_Diabetes, NTproBNP, NetEffectContribution_Additional_GI_surgical_procedure_for_Example_for_GIN_2022, NetEffectContribution_All_cause_mortality_for_Example_for_GIN_2022, NetEffectContribution_New_onset_depression_for_Example_for_GIN_2022, NetEffectContribution_Nonfatal_myocardial_infarction_or_stroke_for_Example_for_GIN_2022, NetEffectContribution_Remission_of_diabetes_for_Example_for_GIN_2022, NetEffectContribution_Treatment_with_opioids_for_Example_for_GIN_2022, NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022, NetEffectEstimate_Bariatric_Surgery_Example_for_GIN_2022, Nonfatal_myocardial_infarction313878, Nonfatal_myocardial_infarction313958, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Comparator_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313878, Nonfatal_myocardial_infarction_Intervention_Evidence_from_MAGICapp_313958, Nonfatal_myocardial_infarction_from_MAGICapp_313878, Nonfatal_myocardial_infarction_from_MAGICapp_313958, Nonfatal_stroke313879, Nonfatal_stroke313959, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Comparator_Evidence_from_MAGICapp_313959, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313879, Nonfatal_stroke_Intervention_Evidence_from_MAGICapp_313959, Nonfatal_stroke_from_MAGICapp_313879, Nonfatal_stroke_from_MAGICapp_313959, Ntprobnp_comparator, Ntprobnp_date, Ntprobnp_time, Ntprobnp_unit, Number_of_Patients_Requiring_Step_up_Treatment_NCT03640312, Organ_support_free_days, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_Diabetes_in_remission, OutcomeDefinition_HbA1c_at_12_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_6_months, OutcomeDefinition_New_onset_depression, OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Additional_GI_surgical_procedure, OutcomeVariable_All_cause_mortality, OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years, OutcomeVariable_HbA1c_at_12_months, OutcomeVariable_HbA1c_at_24_months, OutcomeVariable_HbA1c_at_36_months, OutcomeVariable_HbA1c_at_60_months, OutcomeVariable_HbA1c_at_6_months, OutcomeVariable_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, OutcomeVariable_New_onset_depression, OutcomeVariable_Nonfatal_myocardial_infarction_or_stroke, OutcomeVariable_Remission_of_diabetes, OutcomeVariable_Treatment_with_opioids, Outcome_Death_or_Major_Traumatic_Injury_30_days_after_Impact, Outcome_Death_or_Major_Traumatic_Injury_on_Impact, Outcome_Injury_Severity_Score_30_days_after_Impact, Outcome_Injury_Severity_Score_on_Impact, PARACHUTE_Trial_Participants_available_for_randomization, PARACHUTE_Trial_Participants_deemed_unsuitable_by_investigator, PARACHUTE_Trial_Participants_randomized_into_groups, PARACHUTE_Trial_Participants_randomized_into_groups_for_screened_group, PARACHUTE_Trial_Participants_randomized_into_groups_with_comparator, PARACHUTE_Trial_Participants_randomized_into_groups_with_intervention, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_30_day_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_comparator, PARACHUTE_Trial_Participants_that_completed_jump_and_5_minute_follow_up_with_intervention, PARACHUTE_Trial_Participants_that_declined_randomization, PARACHUTE_Trial_Participants_with_no_contact_at_30_days, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_comparator, PARACHUTE_Trial_Participants_with_no_contact_at_30_days_with_intervention, Parachute_vs_Empty_Backpack_in_PARACHUTE_Trial, ParticipantFlowEvidence_2018_Norwegian_Cohort_Excluded_from_Analysis, ParticipantFlowMeasure_Dropout_due_to_stopping_intervention, ParticipantFlowMeasure_Exclusion_from_analysis, ParticipantFlowMeasure_Inclusion_in_analysis, ParticipantFlow_2018_Norwegian_Cohort_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Medical_Group_Included_in_Analysis, ParticipantFlow_2018_Norwegian_Cohort_Surgical_Group_Included_in_Analysis, Participants_Excluded_from_PARACHUTE_Study, Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill, Patient_id, Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill, Percentage_of_Participants_With_Potentially_Related_Adverse_Events_NCT03640312, Percentage_of_Participants_With_Serious_Adverse_Events_SAEs_NCT03640312, Placebo, PlanDefinition/179468, PlanDefinition/179554, PlanDefinition/181450, Proportion_of_Patients_With_Adverse_Event_Free_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_12_weeks_at_NCT03640312, Proportion_of_Patients_With_Hypertension_Control_at_6_and_12_weeks_6_weeks_at_NCT03640312, QUARTET_Eligibility_Criteria, Randomized_into_groups_for_PARACHUTE_Trial, Rate_of_Adverse_Events_of_Special_Interest_NCT03640312, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_comparator, Rate_of_Death_or_Major_Traumatic_Injury_on_Impact_with_intervention, Reasons_for_exclusion_from_QUARTET_USA_Trial, Remdesivir, Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days, Risk_of_bias_type, SEQN, Sample_ID, SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review, SearchStrategy_PubMed_search_for_Wonder_Woman, Self_reported_race, Self_reported_sex, Serious_hyperglycaemia313882, Serious_hyperglycaemia313963, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Comparator_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882, Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313963, Serious_hyperglycaemia_from_MAGICapp_313882, Serious_hyperglycaemia_from_MAGICapp_313963, Severe_gastrointestinal_events313883, Severe_gastrointestinal_events313965, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Comparator_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313883, Severe_gastrointestinal_events_Intervention_Evidence_from_MAGICapp_313965, Severe_gastrointestinal_events_from_MAGICapp_313883, Severe_gastrointestinal_events_from_MAGICapp_313965, Severely_Obese_Adults_2018_Norwegian_Cohort, Sex, Sex_with_comparator, Sex_with_intervention, Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798, Source_of_sample, Spanish_or_English_Value_Set, Standard_care85390_C_85789, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, StudyEligibilityCriteria_Obese_patients_18_years_old, StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group, StudyGroup_DIBASY_Trial_Enrollment_Group, Subject_ID, Subject_age_at_diagnosis, SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer, Systolic_blood_pressure_at_12_weeks, Technology_employed_on_the_sample, The_tumor_status_of_the_sample, Therapeutic_dose_anticoagulation_with_heparin_vs_Usual_care_pharmacologic_thromboprophylaxis, Time_to_integration_of_results_in_a_recommendation, Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, Velocity, Velocity_comparing_intervention_vs_comparator, Velocity_for_enrolled_group, Velocity_for_non_participant_group, Velocity_with_comparator, Velocity_with_intervention, WTSAF2YR, Weight, Weight_with_comparator, Weight_with_intervention and Year_2018_Norwegian_Cohort_Study * EvidenceVariableRole: Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY ( src )
• author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )
• author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter: , Joanne Dehnbostel: ( src )
• author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: ( src )
• author: Computable Publishing®: MAGIC-to-FEvIR Converter: ( src )
• author: Computable Publishing®: MEDLINE-to-FEvIR Converter: ( src )
• title: SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter ( src )
• © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. ( src )
• © 2020 by the American Diabetes Association. ( src )
• © 2021-2025 Computable Publishing LLC, Patent Pending. ( src )
• © 2024+ HL7 International / Clinical Decision Support. ( src )
• © 2024. The Author(s). ( src )
• © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. ( src )
• © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ( src )
• © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. ( src )

External References

Internal Images

tree-filter.png